MUC-1 peptide-loaded dendritic cells + cytokine-induced killer cells

MUC-1 peptide-loaded dendritic cells + cytokine-induced killer cells is an investigational combination immunotherapy designed for cancer treatment. This therapy involves two main components: - Dendritic cells (DCs) are harvested from the patient and loaded ex vivo with a synthetic peptide derived from the tumor-associated antigen mucin 1 (MUC1), which is overexpressed in many adenocarcinomas, including pancreatic cancer. These antigen-pulsed DCs are then administered back to the patient to stimulate a targeted anti-tumor immune response by presenting the MUC1 antigen to T-cells[1][3]. - Cytokine-induced killer (CIK) cells are a heterogeneous population of immune effector cells generated by culturing peripheral blood mononuclear cells with interferon-gamma, anti-CD3 antibody, and interleukin-2. CIKs possess potent non-MHC-restricted cytotoxicity against tumor targets. The combination aims to enhance both specific adaptive immunity via DC vaccination and broad innate-like cytotoxicity via CIK infusion. The primary indication under investigation has been pancreatic cancer, particularly as adjuvant or advanced disease therapy[1][3]. Early-phase clinical trials have demonstrated safety and immunogenicity; efficacy data remain preliminary.

Other names

MUC-1 peptide-loaded DCs + CIKsMUC1-pulsed dendritic cell and CIK therapyMUC-1-pulsed dendritic cell and CIK therapyMUC 1-pulsed dendritic cell and CIK therapy